HISTORICAL FACTS: 23 - Caught on Camera

48 Stocks Moving In Friday's Mid-Day Session

 Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.

Benzinga · Apr 29, 2022

AstraZeneca boss calls for UK to provide new Covid-19 medicine to the vulnerable

Pharmaceutical CEO says it’s ‘sad’ that UK has failed to order Evusheld for the immunosuppressed

The Guardian - UK · Apr 29, 2022

The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Apr 29, 2022

How To Attend AstraZeneca Q1 2022 Earnings Conference Call

  AstraZeneca (NASDAQ:AZN) will host a conference call at 06:45 AM ET on April 29, 2022, to discuss Q1 2022 earnings results. How to Attend AstraZeneca (AZN) Conference Call Follow this link to access the live webcast.

Benzinga · Apr 25, 2022

Latest data shows significant rise in Covid deaths in England and Wales for third week in a row

Deaths involving Covid-19 are up 13 per cent on last week, the latest data shows

Manchester Evening News · Apr 21, 2022

If You Invested $100 In AstraZeneca 5 Years Ago, Here's How Much You Would Have Today

AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 4.24% on an annualized basis producing an average annual return of 17.72%. Currently, AstraZeneca has a market capitalization of $213.61 billion.

Benzinga · Apr 21, 2022

Covid booster gives long-lasting protection, study finds

'The longer-term protection against hospitalisation and death is perhaps the most important factor for future booster programmes'

Wales Online · Apr 21, 2022

Third Covid-19 vaccine dose offers ‘prolonged immune response’ – UK-wide study

The study compared immune responses to seven vaccines used as a booster 28 days after two initial doses.

The Independent UK · Apr 21, 2022

AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals

AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo.  There were no…

Benzinga · Apr 21, 2022

Covid-19 vaccine maker Oxford Biomedica pauses production as AstraZeneca partnership reviewed

Shares in the FTSE 250 company slumped as much as 10% as it warned revenues will be lower this year than last

Evening Standard · Apr 20, 2022